Redo in aortic homograft replacement: transcatheter aortic valve as a valid alternative to surgical replacement.
Department of Cardiovascular Surgery, University of Milan, Centro Cardiologico Monzino IRCCS, 20138 Milan, Italy.The Journal of thoracic and cardiovascular surgery (Impact Factor: 3.41). 09/2009; 139(6):1656-7. DOI:10.1016/j.jtcvs.2009.07.006
Article: 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.Catheterization and Cardiovascular Interventions 01/2012; 79(7):1023-82. · 2.51 Impact Factor
- European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery 03/2012; 42(3):603; author reply 604. · 2.40 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: Transcatheter aortic valve implantation (TAVI) has become a viable alternative in maximum risk patients. For those patients requiring aortic valve re-replacement, the "valve-in-valve" concept has been described. We report our experience with transapical valve-in-valve implantation in 7 patients with deteriorated aortic bioprosthesis at 1-year follow up. Since November 2008, 210 patients received transapical TAVI due to severe aortic stenosis. Seven patients presented with deteriorated aortic valve bioprosthesis and received transapical valve-in-valve implantation. Mean age was 78.7±0.8 years. Preoperatively, all patients were at New York Heart Association (NYHA) functional class III. For risk estimation, the Society of Thoracic Surgeons (STS) and European System for Cardiac Operative Risk Evaluation (ES) risk scores were used and predicted high mortality (means±standard error of the mean: STSMortality 21.6±2.8%, ESadd 14.9±1.1, ESlog 52.6±9.0%). Mean follow-up time was 517±65 days (range, 280 to 799 days). Six patients showed a severely deteriorated bioprosthesis in terms of a stenotic valve (aortic valve area: 0.64±0.04 cm2, maximum/mean developed transvalvular pressure gradient: dPmax 63.3±10.9 mm Hg, dPmean 40.4±5.6 mm Hg). One patient's deteriorated prosthesis was highly insufficient. Procedural success rate was 100%, mean procedure time was 46.7±12.3 minutes. Echocardiography revealed excellent hemodynamics of implanted prosthesis (dPmax 31.1±5.5 mm Hg; dPmean 19.4±4.3 mm Hg). Overall, postoperative course was uneventful. No patient died during follow-up, which ranged up to 26 months. All patients, except 1, remained in NYHA class I or II. Our results demonstrate feasibility and safety of the transapical valve-in-valve approach with excellent hemodynamic and clinical results. Decision making in a multidisciplinary setting is mandatory. Further studies with more patients and longer follow-up are needed to identify candidates benefiting from transapical transcatheter valve-in-valve implantation.The Annals of thoracic surgery 03/2012; 93(3):734-41. · 3.74 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.